View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Chemung Financial Corporation Announces Quarterly Dividend

Chemung Financial Corporation Announces Quarterly Dividend ELMIRA, N.Y., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Chemung Financial Corporation (Nasdaq: CHMG) announced today that its Board of Directors has approved a quarterly cash dividend of $0.34 per share, payable on April 1, 2026, to common stock shareholders of record as of the close of business on March 18, 2026. Chemung Financial Corporation is a $2.7 billion financial services holding company headquartered in Elmira, New York and operates 30 offices through its principal subsidiary, Chemung Canal Trust Company, a full-service communit...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: February 14, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business High...

Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights FORT LEE, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the year ended December 31, 2025 and provided an update on recent business progress. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, “2025 was an eventfu...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: February 7, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: February 6, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: February 4, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Bi...

Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 4:00 p.m. ET in New York, NY. A live webcast of the fireside ch...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: February 3, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Origin Bancorp, Inc. Reports Earnings for Fourth Quarter and Full Year...

Origin Bancorp, Inc. Reports Earnings for Fourth Quarter and Full Year 2025 RUSTON, La., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Origin Bancorp, Inc. (NYSE: OBK) (“Origin,” “we,” “our” or the “Company”), the holding company for Origin Bank (the “Bank”), today announced net income of $29.5 million, or $0.95 diluted earnings per share (“EPS”) for the quarter ended December 31, 2025, compared to net income of $8.6 million, or $0.27 diluted EPS, for the quarter ended September 30, 2025. Pre-tax, pre-provision (“PTPP”)(1) earnings were $40.6 million for the quarter ended December 31, 2025, compared ...

 PRESS RELEASE

Origin Bancorp, Inc. Announces Declaration of Quarterly Cash Dividend

Origin Bancorp, Inc. Announces Declaration of Quarterly Cash Dividend RUSTON, La., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Origin Bancorp, Inc. (NYSE: OBK) ("Origin"), the holding company for Origin Bank, today announced that on January 28, 2026, its board of directors declared a quarterly cash dividend of $0.15 per share of its common stock. The cash dividend will be paid on February 27, 2026, to stockholders of record as of the close of business on February 13, 2026. About Origin Bancorp, Inc. Origin Bancorp, Inc. is a financial holding company headquartered in Ruston, Louisiana. Origin’s w...

 PRESS RELEASE

Chemung Financial Corporation Reports Fourth Quarter 2025 Net Income o...

Chemung Financial Corporation Reports Fourth Quarter 2025 Net Income of $7.7 million, or $1.61 per share & Annual Financial Results ELMIRA, N.Y., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Chemung Financial Corporation (the “Corporation”) (Nasdaq: CHMG), the parent company of Chemung Canal Trust Company (the “Bank”), today reported net income of $7.7 million, or $1.61 per share, for the fourth quarter of 2025, compared to net income of $7.8 million, or $1.62 per share, for the third quarter of 2025, and net income of $5.9 million, or $1.24 per share, for the fourth quarter of 2024. Annual net inco...

 PRESS RELEASE

Origin Bancorp, Inc. Announces Fourth Quarter and Full Year 2025 Earni...

Origin Bancorp, Inc. Announces Fourth Quarter and Full Year 2025 Earnings Release and Conference Call RUSTON, La., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Origin Bancorp, Inc. (NYSE: OBK) (“Origin”), the financial holding company for Origin Bank, plans to issue fourth quarter and full year 2025 results after the market closes on Wednesday, January 28, 2026, and hold a conference call to discuss such results on Thursday, January 29, 2026, at 8:00 a.m. Central Time (9:00 a.m. Eastern Time). The conference call will be hosted by Drake Mills, Chairman, President and CEO of Origin, William J. Wallac...

 PRESS RELEASE

Milestone Scientific Launches The Wand® Ambassador Program to Expand P...

Milestone Scientific Launches The Wand® Ambassador Program to Expand Peer Engagement and Accelerate Market Adoption in Dentistry Pilot launched with six registered dental professionals; program expected to scale to 250 ambassadors over 12 months ROSELAND, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the launch of The Wand® Ambassador Program, a scalable peer-to-peer engagement initiative designed to expand clinical awareness, educ...

 PRESS RELEASE

Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated...

Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones Multiple clinical data readouts expected in 2026 present opportunity for substantial value creation KOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026 Plans to conduct NMRA-215 clinical program in 2026 following class-leading preclinical data from diet induced obesity model Advancing NMRA-511 following Phase 1b results demonstrating clinically meaningful effect on CMAI total score Cash, cash equivalents and marketable securities expected to support operation...

 PRESS RELEASE

Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b...

Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer’s Disease Agitation NMRA-511 demonstrated a 15.7 reduction on mean CMAI total score, representing a clinically meaningful effect  NMRA-511 demonstrated unsurpassed clinical effect size on CMAI total score in a pre-specified population with elevated anxiety NMRA-511 demonstrated a favorable tolerability and safety profile Neumora plans to evaluate higher doses of NMRA-511 via initiation of a multiple ascending dose expansion cohort in 2026 Company to host conference call today at 8:0...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: December 19, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch